Company intelligence / Profile preview

Petra Pharma Corporation

New York, New York, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Petra Pharma was developing serabelisib and planned to initiate a Phase Ib/II study in late 2019 focusing on PIK3CA-mutated solid tumors. The company was acquired by a global pharmaceutical company in 2020.

Therapeutic areas: OncologyMetabolic Disorders
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

serabelisib

Phase 2

Indications: PIK3CA-mutated solid tumors, Recurrent Endometrial Cancer

1 more asset in the full pipeline.

Request access →

Partnerships

Takeda

Beyond the preview

Go deeper on Petra Pharma Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Petra Pharma Corporation.

Explore the full profile